Committee Chairman Sen. Chuck Grassley, R-Iowa, and ranking member Sen. Ron Wyden, D-Ore., invited leaders from AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi.
The four executives scheduled to attend the Feb. 26 hearing are: Bristol Myers CEO Giovanni Caforio, MD; Merck CEO Ken Frazier; Pfizer CEO Albert Bourla, PhD; and Sanofi CEO Olivier Brandicourt, MD.
The other three drugmakers didn’t immediately respond to the invite.
The Senate Finance Committee held an initial hearing on drug prices in January. During the hearing, Mr. Grassley expressed disappointment about drug executives’ lack of attendance and commented he would be “more insistent” that executives show up at a subsequent meeting.
More articles on pharmacy:
Senate committee invites 7 pharma leaders to testify at drug price hearing
Bernie Sanders takes aim at drug’s $375K price tag
Walgreens buys 63 pharmacies out of bankruptcy
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
